Danske Bank’s Karyopharm Therapeutics KPTI Stock Holding History

Danske Bank’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-3	Closed	-$11	–	1563
2025 Q1	$11	Buy	+3	New	+$26	﹤0.01%	1317

Other funds holding KPTI

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Danske Bank's KPTI Position: Q2 2025 in Review

Danske Bank sold out of Karyopharm Therapeutics (KPTI) in Q2 2025, closing a stake of 3 shares — an estimated $11 sold.

Danske Bank first reported a position in KPTI in Q1 2025 and held it in 1 quarter. The position peaked at $11 in Q1 2025. 50 funds tracked by Wall St. Rank hold KPTI as of Q2 2025.

Danske Bank reported no remaining Karyopharm Therapeutics position as of Q2 2025 after selling out during the quarter.
Danske Bank sold 3 Karyopharm Therapeutics shares in Q2 2025, an estimated $11.
Danske Bank first reported a position in Karyopharm Therapeutics in Q1 2025 and held it in 1 quarter.
Danske Bank's Karyopharm Therapeutics position peaked at $11 in Q1 2025.
50 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2025.

Based on Danske Bank's 13F filing for Q2 2025, filed 18 Dec 2025.